Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Long-Term Investments (2018 - 2025)

Addex Therapeutics' Long-Term Investments history spans 8 years, with the latest figure at $636929.3 for Q4 2025.

  • On a quarterly basis, Long-Term Investments fell 92.13% to $636929.3 in Q4 2025 year-over-year; TTM through Dec 2025 was $636929.3, a 92.13% decrease, with the full-year FY2025 number at $614000.2, down 92.41% from a year prior.
  • Long-Term Investments came in at $636929.3 for Q4 2025, up from $8859.5 in the prior quarter.
  • The five-year high for Long-Term Investments was $8.1 million in Q4 2024, with the low at $7816.9 in Q2 2024.
  • Historically, Long-Term Investments has averaged $505868.5 across 5 years, with a median of $60855.8 in 2023.
  • Biggest five-year swings in Long-Term Investments: surged 13105.15% in 2024 and later tumbled 92.13% in 2025.
  • Year by year, Long-Term Investments stood at $62801.3 in 2021, then dropped by 10.16% to $56421.7 in 2022, then rose by 8.58% to $61265.0 in 2023, then skyrocketed by 13105.15% to $8.1 million in 2024, then plummeted by 92.13% to $636929.3 in 2025.
  • Business Quant data shows Long-Term Investments for ADXN at $636929.3 in Q4 2025, $8859.5 in Q3 2025, and $614897.1 in Q2 2025.